Exenatide has a better hepatic-protective effect than intensive insulin therapy and, perhaps, represents a unique option for adjunctive therapy for patients with obesity, NAFLD with elevated liver enzymes and T2DM [182]. Here, INS is linked to obesity due to melanocortin 4 receptor deficiency.